Articles From: Vail Resorts Reports Fiscal 2014 Fourth Quarter and Full Year Results and Provides Fiscal 2015 Outlook to Valero Energy Corporation Provides Second Quarter 2014 Interim Update


2014/9/17
- EpicPromise expands Vail Resorts' leadership in sustainability by engaging guests, local communities and employees in the commitment to create a more promising future.
Sign-up for Vail Resorts Strengthens Commitment to Sustainability with Launch of EpicPromise investment picks
By Wayne Ma Brazilian mining giant Vale S.A. (VALE) said Friday it signed a deal with state-owned China Ocean Shipping (Group) Co.
Sign-up for Vale, Cosco Group To Cooperate On Iron-Ore Shipping investment picks
NEW YORK (MarketWatch) -- Valeant Pharmaceuticals International Inc. (VRX) said Monday it has contacted regulators in the U.S. and Canada to complain that Allergan Inc. (AGN) has made misleading statements about Valeant's Bausch + Lomb unit.
Sign-up for Valeant accuses Allergan of making misleading statements investment picks
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 Canada NewsWire LAVAL, Quebec , Sept.
Sign-up for Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 investment picks
LOS ANGELES (MarketWatch) -- Valeant Pharmaceuticals International Inc. (VRX) on Friday called Allergan Inc.'s (AGN) filing of a federal lawsuit "frivolous" and said it was an effort to interfere with the calling of a special shareholder vote on Valeant's $53 billion for Allergan.
Sign-up for Valeant calls Allergan lawsuit 'frivolous' investment picks
LAVAL, Quebec , Aug.
Sign-up for Valeant Extends Offer To Acquire Allergan investment picks
NEW YORK (MarketWatch) -- Valeant Pharmaceuticals International Inc. (VRX) said Thursday it has filed an official and detailed complaint with the Canadian regulator, Autorite des Marches Financiers, about statements made by Allergan Inc. (AGN) regarding Valeant's business.
Sign-up for Valeant files official complaint about Allergan with Canadian regulator investment picks
By Lauren Pollock and Chelsey Dulaney Valeant Pharmaceuticals International Inc. said it expects to report stronger-than-expected results for its third quarter and continued its push to bring Botox maker Allergan Inc. to the negotiating table as their takeover battle enters its fifth month.
Sign-up for Valeant offers olive branch to Allergan investment picks
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit Desperate Allergan Attempt to Interfere with the Special Meeting Canada NewsWire LAVAL, Quebec and NEW YORK , Aug.
Sign-up for Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit investment picks
Desperate Allergan Attempt to Interfere with the Special Meeting LAVAL, Quebec and NEW YORK , Aug.
Sign-up for Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit investment picks
Corrects Allergan's False Statements Regarding Bausch + Lomb Performance LAVAL, Quebec , July 21, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has contacted both the Autorite des marches financiers ("AMF") in Quebec and the U.S. Securities and Exchange Commission ("SEC") regarding Allergan Inc.'s (NYSE: AGN) apparent attempt to mislead investors and manipulate the market for Valeant common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information.
Sign-up for Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements investment picks
2014/9/8
Hosted Ribbon Cutting Ceremony for the New Bausch + Lomb ULTRA® Contact Lens Manufacturing Line and Solar Array Implementation LAVAL, Quebec , Sept.
Sign-up for Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester investment picks
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements Canada NewsWire LAVAL, Quebec , July 24, 2014 /CNW/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting this misinformation.
Sign-up for Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements investment picks
LAVAL, Quebec , July 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting this misinformation.
Sign-up for Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements investment picks
Valeant Pharmaceuticals Files Investor Presentation Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume Allergan Stockholders Encouraged to Call Special Meeting Valeant to Announce Second Quarter 2014 Financial Results on July 31, 2014 Canada NewsWire LAVAL, Quebec , July 18, 2014 /CNW/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting.
Sign-up for Valeant Pharmaceuticals Files Investor Presentation investment picks
Bausch + Lomb's Organic Growth 12% for the Second Quarter of 2014, over 90% Due to Volume Allergan Stockholders Encouraged to Call Special Meeting Valeant to Announce Second Quarter 2014 Financial Results on July 31, 2014 LAVAL, Quebec , July 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) has filed an investor presentation with the Securities and Exchange Commission that will be used in meetings with Allergan's institutional investors and proxy advisors, the first of which is being held today, regarding calling a special meeting.
Sign-up for Valeant Pharmaceuticals Files Investor Presentation investment picks
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Canada NewsWire LAVAL, Quebec , July 31, 2014 /CNW/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
LAVAL, Quebec , July 31, 2014 /PRNewswire/ -- 2014 Second Quarter Total Revenue $2.0 billion ; an increase of 86% over the prior year Overall organic growth was 4% for same store sales and 8% pro forma, excluding divested facial injectable products; Bausch + Lomb grew 12% 2014 Second Quarter GAAP EPS $0.37 ; Cash EPS $1.91 , an increase of 43% 2014 Second Quarter GAAP Operating Cash Flow $376 million ; Adjusted Operating Cash Flow $500 million Highlights of the Second Quarter Launched 17 new products in the U.S. year-to-date Sold facial injectable assets to Galderma S.A. for approximately $1.4 billion ; $300+ million gain Proceeds will be used to fund Allergan and/or deploy on additional business development opportunities Received FDA approval for Jublia® earlier than expected; stronger than anticipated label Reached agreement with Irish Government and Unions to successfully restructure
Sign-up for Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan Canada NewsWire LAVAL, Quebec , July 14, 2014 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN) .
Sign-up for Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan investment picks
LAVAL, Quebec , July 14, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN) .
Sign-up for Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan investment picks
Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA Canada NewsWire LAVAL, Quebec , Sept.
Sign-up for Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA investment picks
LAVAL, Quebec , Sept.
Sign-up for Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA investment picks
Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in Third Quarter Bausch + Lomb Expected to Continue to Deliver Greater Than 10% Organic Growth (unadjusted) Valeant 3Q Results Expected to Beat Consensus on Revenue and Be Better than Guidance on Cash EPS, Organic Growth, Restructuring Charges and Adjusted Cash Flow from Operations Expect Continued Strong Double-digit Same Store Organic Growth in the Fourth Quarter Will Announce Third Quarter Results on October 20 LAVAL, Quebec , Sept.
Sign-up for Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director investment picks
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Canada NewsWire Overall Same Store Organic Growth (unadjusted for generics) Expected to Exceed 15% in Third Quarter Bausch + Lomb Expected to Continue to Deliver Greater Than 10% Organic Growth (unadjusted) Valeant 3Q Results Expected to Beat Consensus on Revenue and Be Better than Guidance on Cash EPS, Organic Growth, Restructuring Charges and Adjusted Cash Flow from Operations Expect Continued Strong Double-digit Same Store Organic Growth in the Fourth Quarter Will Announce Third Quarter Results on October 20 LAVAL, Quebec , Sept.
Sign-up for Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director investment picks
Valeant Pharmaceuticals International Inc. (VRX) and partner Pershing Square Capital Management plan to boost their bid for Allergan Inc. (AGN) by $15 a share, The Wall Street Journal reported late Tuesday, citing unnamed sources.
Sign-up for Valeant to boost Allergan bid by $15 a share: report investment picks
2014/7/29
SAN ANTONIO , July 29, 2014 /PRNewswire/ -- The Board of Directors of Valero Energy Corporation (NYSE: VLO, "Valero") has approved an increase in the company's regular quarterly cash dividend on common stock from $0.25 per share to $0.275 , effective with the quarterly dividend the Board has declared to be payable on September 17, 2014 to holders of record at the close of business on August 20, 2014 .
Sign-up for Valero Energy Corporation Increases Regular Cash Dividend on Common Stock investment picks
2014/7/14
SAN ANTONIO , July 14, 2014 /PRNewswire/ -- Valero Energy Corporation (NYSE: VLO, "Valero") announced today that the company expects to report income from continuing operations in the range of $1.10 to $1.25 per share for the second quarter of 2014.
Sign-up for Valero Energy Corporation Provides Second Quarter 2014 Interim Update investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Vail Resorts Reports Fiscal 2014 Fourth Quarter and Full Year Results and Provides Fiscal 2015 Outlook to Valero Energy Corporation Provides Second Quarter 2014 Interim Update
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices